<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832620</url>
  </required_header>
  <id_info>
    <org_study_id>41335</org_study_id>
    <nct_id>NCT04832620</nct_id>
  </id_info>
  <brief_title>Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas</brief_title>
  <acronym>CHIPT</acronym>
  <official_title>Defining Optimal Imaging Strategies for Diagnosis, Treatment, and Treatment Evaluation of Chordomas and Chondrosarcomas of the Axial Skeleton</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HollandPTC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Varian Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Chordomas and chondrosarcomas located in the axial skeleton are malignant&#xD;
      neoplasms of bone. These tumors share the same clinical challenges, as the effect of the&#xD;
      disease is more a function of their local aggressiveness than their tendency to metastasize&#xD;
      (20% metastasize). The local aggressive behavior can cause debilitating morbidity and&#xD;
      mortality by destruction of nearby located critical neurovascular structures. Imaging has, in&#xD;
      addition to histopathology, a role in diagnosis and in guiding (neo)adjuvant and definitive&#xD;
      treatment. Despite the low sensitivity to radiotherapy, proton radiotherapy has been&#xD;
      successfully used as an adjunct to resection or as definitive treatment for aggressive&#xD;
      chordomas and chondrosarcomas, making it a standard indication for proton therapy in the&#xD;
      Netherlands.&#xD;
&#xD;
      Chordomas and chondrosarcomas consist, especially after previous therapy, of non-viable and&#xD;
      viable tumor components. Identification of these viable components by functional imaging is&#xD;
      important to determine the effect of previous therapy, as change in total tumor volume occurs&#xD;
      more than 200 days after change of functional imaging parameters.&#xD;
&#xD;
      Objective: The main objective of this study is to determine if functional MRI parameters&#xD;
      change within 6 months, and earlier than volumetric changes after start of proton beam&#xD;
      therapy. This would allow timely differentiation between affected and unaffected (viable)&#xD;
      tumor components, which can be used for therapy adjustment.&#xD;
&#xD;
      Secondary objectives: Determine which set of parameters (PET-CT and secondary MRI) can&#xD;
      predict clinical outcome (tumor specific mortality, development of metastases, morbidity&#xD;
      secondary to tumor activity and morbidity secondary to treatment); determine what type of&#xD;
      imaging can accurately identify viable tumor nodules relative to critical anatomical&#xD;
      structures; improving understanding of relevance of changing imaging parameters by&#xD;
      correlating these with resected tumor.&#xD;
&#xD;
      Study design: Prospective cohort study Study population: LUMC patients diagnosed with primary&#xD;
      or recurrent chordoma or chondrosarcoma in the axial skeleton. A number of 20 new patients&#xD;
      per year is expected.&#xD;
&#xD;
      Main study parameters: Volumetric and functional MR imaging parameters including permeability&#xD;
      parameters.&#xD;
&#xD;
      Secondary parameters are generated by PET-CT (SUV, MTV and TLG), MR (perfusion, permeability&#xD;
      and diffusion), therapy (proton beam dose mapping, surgery) and clinical outcome. End points&#xD;
      are disease specific survival, progression free survival (including development of&#xD;
      metastases), side effects of treatment, and functional outcome (see CRF). In patients who are&#xD;
      treated with surgical resection following neo-adjuvant therapy, the surgical specimen will be&#xD;
      correlated with imaging findings.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: Treatment and clinical management will not be affected in this study, thus the&#xD;
      additional burden, risks, and benefits associated with participation in this study are&#xD;
      minimal.&#xD;
&#xD;
      Two extra MRI and one PET-CT examination will be planned during proton therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vp(max), Vp(min)</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI permeability parameter - tumor plasma volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rel Enhancement (%)</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI perfusion parameter showing the signal enhancement of a pixel of certain dynamic relative to that same pixel in the reference dynamic. The reference dynamic is normally the first, pre-contrast dynamic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Max Enhancement (%)</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI perfusion parameter showing difference between peak intensity S1 and S0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Max Rel Enhancement (%)</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI perfusion parameter showing maximum of all relative enhancements over all dynamics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of arrival T0 (s)</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI perfusion parameter showing time at which the signal intensity increases for at least 20% compared to the baseline (referred to as initial signal intensity S0).&#xD;
The baseline is the average of the signal intensities of all timepoints before the contrast uptake starts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Peak (s)</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI perfusion parameter showing time till contrast agent bolus reaches peak intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wash In Rate (sˉ¹)</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI perfusion parameter showing maximum slope between T0 and time of peak intensity T1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wash Out Rate (sˉ¹)</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI perfusion parameter showing maximum slope between time of peak intensity T1 and the end of the measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brevity of Enhancement (s)</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI perfusion parameter showing time between point of maximum wash in rate and maximum wash out rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ktrans</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI permeability parameter - transfer constant between blood plasma and Extravascular Extracellular Space (EES), also called vascular permeability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kep</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI permeability parameter showing rate between EES and blood plasma (also called Tracer Efflux Rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ve</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI permeability parameter showing Extravascular Volume fraction (Leakage space); defined as Ktrans / kep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI permeability and perfusion parameter showing area Under the Curve of all time curves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean ADC, Min ADC, Max ADC</measure>
    <time_frame>At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment</time_frame>
    <description>MRI diffusion parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUV</measure>
    <time_frame>At inclusion and and 11 months following the start date fo proton therapy</time_frame>
    <description>Standard uptake value extracted from PET-CT imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MTV</measure>
    <time_frame>At inclusion and and 11 months following the start date fo proton therapy</time_frame>
    <description>Metabolic tumor volume extracted from PET-CT imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLG</measure>
    <time_frame>At inclusion and and 11 months following the start date fo proton therapy</time_frame>
    <description>Total lesion glycolysis extracted from PET-CT imaging</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bone Neoplasm of Vertebral Column</condition>
  <condition>Chordoma</condition>
  <condition>Chondrosarcoma</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <condition>PET-CT</condition>
  <condition>Proton Therapy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred to HollandPTC, or LUMC, or the Netherlands Committee of Bone tumors,&#xD;
        histologically diagnosed with primary or recurrent chordoma or chondrosarcoma in the axial&#xD;
        skeleton (clivus, spine and sacrum), and accepted for standard proton beam therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically diagnosed with primary or recurrent chordoma or chondrosarcoma in the&#xD;
             axial skeleton (clivus, spine and sacrum)&#xD;
&#xD;
          -  Accepted for standard proton beam therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis other than chordoma or chondrosarcoma is made.&#xD;
&#xD;
          -  Patient refuses (parts) of the standard treatment protocol.&#xD;
&#xD;
          -  Patient refuses MRI due to claustrophobia.&#xD;
&#xD;
          -  Patient not suitable for MRI due to the presence of MRI incompatible implants.&#xD;
&#xD;
          -  Incapacitated patients.&#xD;
&#xD;
          -  Patient doesn't allow coded data to be used for analysis.&#xD;
&#xD;
          -  Patient is under 50 years of age.&#xD;
&#xD;
          -  Lesion size less than 1cm.&#xD;
&#xD;
          -  Patients with WHO 3 and higher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stijn Krol, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LUMC/HollandPTC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Bloem, prof. MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stijn Krol, dr. PhD</last_name>
    <phone>+31624539398</phone>
    <email>A.D.G.Krol@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vesna Miladinovic</last_name>
    <phone>+31682225869</phone>
    <email>v.miladinovic@lumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HollandPTC</name>
      <address>
        <city>Delft</city>
        <state>South Holland</state>
        <zip>2629 JH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stijn Krol, MD PhD</last_name>
      <phone>+31624539398</phone>
      <email>A.D.G.Krol@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte van der Vos, PhD</last_name>
      <phone>+31885011186</phone>
      <email>c.vander.vos@hollandptc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Stijn Krol, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <state>South Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stijn Krol, MD PhD</last_name>
      <phone>+31624539398</phone>
      <email>A.D.G.Krol@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Vesna Miladinovic</last_name>
      <phone>+31682225869</phone>
      <email>v.miladinovic@lumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Hans Bloem, prof. MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stijn Krol, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Augustinis D.G. Krol, MD PhD</investigator_full_name>
    <investigator_title>Radiation oncologist</investigator_title>
  </responsible_party>
  <keyword>Chordoma</keyword>
  <keyword>Chondrosarcoma</keyword>
  <keyword>MRI</keyword>
  <keyword>PET-CT</keyword>
  <keyword>Proton therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Chordoma</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

